Image-guided ablation of primary liver and renal tumours

David J. Breen, Riccardo Lencioni

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.

Original languageEnglish (US)
Pages (from-to)175-186
Number of pages12
JournalNature Reviews Clinical Oncology
Volume12
Issue number3
DOIs
StatePublished - Mar 28 2015
Externally publishedYes

Fingerprint

Ablation Techniques
Kidney
Kidney Neoplasms
Liver
Liver Neoplasms
Neoplasms
Therapeutics
Standard of Care
Nephrectomy
Renal Cell Carcinoma
Hepatocellular Carcinoma
Guidelines

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Image-guided ablation of primary liver and renal tumours. / Breen, David J.; Lencioni, Riccardo.

In: Nature Reviews Clinical Oncology, Vol. 12, No. 3, 28.03.2015, p. 175-186.

Research output: Contribution to journalArticle

Breen, David J. ; Lencioni, Riccardo. / Image-guided ablation of primary liver and renal tumours. In: Nature Reviews Clinical Oncology. 2015 ; Vol. 12, No. 3. pp. 175-186.
@article{56a1e74738054887ba6aeaaf02997b43,
title = "Image-guided ablation of primary liver and renal tumours",
abstract = "Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.",
author = "Breen, {David J.} and Riccardo Lencioni",
year = "2015",
month = "3",
day = "28",
doi = "10.1038/nrclinonc.2014.237",
language = "English (US)",
volume = "12",
pages = "175--186",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Image-guided ablation of primary liver and renal tumours

AU - Breen, David J.

AU - Lencioni, Riccardo

PY - 2015/3/28

Y1 - 2015/3/28

N2 - Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.

AB - Image-guided ablation (IGA) techniques have evolved considerably over the past 20 years and are increasingly used to definitively treat small primary cancers of the liver and kidney. IGA is recommended by most guidelines as the best therapeutic choice for patients with early stage hepatocellular carcinoma (HCC)-defined as either a single tumour smaller than 5 cm or up to three nodules smaller than 3 cm-when surgical options are precluded, and has potential as first-line therapy, in lieu of surgery, for patients with very early stage tumours smaller than 2 cm. With regard to renal cell carcinoma, despite the absence of any randomized trial comparing the outcomes of IGA with those of standard partial nephrectomy, a growing amount of data demonstrate robust oncological outcomes for this minimally invasive approach and testify to its potential as a standard-of-care treatment. Herein, we review the various ablation techniques, the supporting evidence, and clinical application of IGA in the treatment of primary liver and kidney cancers.

UR - http://www.scopus.com/inward/record.url?scp=84923817508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923817508&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2014.237

DO - 10.1038/nrclinonc.2014.237

M3 - Article

C2 - 25601446

AN - SCOPUS:84923817508

VL - 12

SP - 175

EP - 186

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 3

ER -